Sichenzia Ross Friedman Ference LLP Represents Aridis Pharmaceuticals in $15 Million Private Placement
PRESS RELEASE – New York, NY – August 25, 2016 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP is pleased to announce that the firm has represented Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, in a private placement of preferred stock and warrants resulting in total gross proceeds of $15,216,241.
Maxim Merchant Capital, a division of Maxim Group LLC, acted as the exclusive placement agent for the offering. The Sichenzia Ross Friedman Ference LLP team was led by Partner Jeff Fessler, Avital Even-Shoshan, Evan Berger and Nazia Khan.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference Represents Pareteum Corporation in Tender Offer for Shares of iPass, Inc. and Completes Acquisition - February 14, 2019
- Sichenzia Ross Ference Partner Ralph Preite Participates on Financial Poise’s “Legal Ethics – Best Practices” Webinar - February 14, 2019
- Sichenzia Ross Ference LLP Adds Jeff D’Angelo as Corporate & Securities Partner - February 13, 2019